Home >   Products   >  Advanced Search

Carbinoxamine Maleate
(CAS RN:3505-38-2 Product Number:C3057)

Structure

Carbinoxamine Maleate

General Information

Product Number C3057

* Items available from stock in Japan will be delivered in 10 business days.
* Please contact us if you need further information.
(Sales Dept Tel: +32 (0)3 735 07 00 E-mail: Sales-EU@TCIchemicals.com)
* To send your quote request for bulk quantities, please click on the “Request Bulk Quotation” button. Please note that for some of our products we cannot offer bulk quantities.
* TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.

Purity/Analysis Method >98.0%(HPLC)(T)
Storage Temperature
M.F. / M.W. C16H19ClN2O·C4H4O4=406.86
CAS RN 3505-38-2
Related CAS RN 486-16-8
MDL Number MFCD00082461
Packaging and Container
  • Product Details
  • Safety & Regulations

Specification

Appearance White to Almost white powder to crystal
Purity(HPLC) min. 98.0 %(total of Ion-Pair)
Purity(Nonaqueous Titration) min. 98.0 %
Melting point 116.0 to 121.0 deg-C

References

Reaxys-RN 6557352
PubChem SID 253662526
Merck Index(14) 1799
RTECS# US6350000
EC Number 222-498-0

GHS

Pictogram
Signal Word Danger
Hazard Statements
  • H301
  • :Toxic if swallowed.
Precautionary Statements
  • P264
  • :Wash hands and face thoroughly after handling.
  • P270
  • :Do not eat, drink or smoke when using this product.
  • P301+P310+P330
  • :IF SWALLOWED: Immediately call a POISON CENTER or doctor. Rinse mouth.
  • P405
  • :Store locked up.
  • P501
  • :Dispose of contents/container through a waste management company authorized by the local government.

Transport Information

UN Number 2811
Class 6.1
Packing Group III
HS Number 2933399990

Application

Carbinoxamine maleate: A Histamine H1-Receptor Antagonist.

Carbinoxamine maleate, a first generation antihistamine, is a histamine H1-receptor antagonist. Carbinoxamine competes with histamine (type H1) for receptor sites on effector cells in the gastrointestinal tract, blood vessels and respiratory tract.

References

PubMed Literature

Page Top